Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Introduction This multicenter, open-label, phase II study was carried out to compare the efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface integrins αVβ3 and αVβ5, with that of docetaxel in patients with advanced non-small-cell lung cancer (NSCLC). Methods Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Manegold, Christian, Vansteenkiste, Johan, Cardenal, Felipe, Schuette, Wolfgang, Woll, Penella J., Ulsperger, Ernst, Kerber, Anne, Eckmayr, Josef, von Pawel, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553405/
https://www.ncbi.nlm.nih.gov/pubmed/22752690
http://dx.doi.org/10.1007/s10637-012-9842-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553405/
https://www.ncbi.nlm.nih.gov/pubmed/22752690
http://dx.doi.org/10.1007/s10637-012-9842-6

Ejemplares similares